Raymond Prudo-Chlebosz - 01 Jan 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Rachelle Jacques, as Attorney-in-Fact for Raymond Prudo-Chlebosz, M.D.
Issuer symbol
AKTX
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
3
Filing time
02 Jan 2024, 18:58:40 UTC
Next filing
04 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 2,331,580,600 01 Jan 2024 Direct
holding AKTX Ordinary Shares, par value $0.0001 per share 38,709,600 01 Jan 2024 Praxis Trustees Limited
holding AKTX Ordinary Shares, par value $0.0001 per share 800,766,600 01 Jan 2024 RPC Pharma Limited

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 10,000,000 $0.001700 Direct F1
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 9,210,500 $0.0300 RPC Pharma Limited
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 7,500,000 $0.0220 Direct
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 20,229,700 $0.0165 Direct
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 41,666,700 $0.0140 Direct
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 117,647,100 $0.008500 Direct
holding AKTX Warrants (Right to Buy) 01 Jan 2024 Ordinary Shares, par value $0.0001 per share 117,647,100 $0.008500 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2024 Annual General Meeting.

Remarks:

See Exhibit 24.1 - Power of Attorney